Mayim Bialik's Breakdown - 50 Million in Funding, 10,000 New Clinics, and the Mistake That Could Kill the Psychedelic Revolution | Dr. Rick Doblin

Episode Date: June 2, 2026

Dr. Rick Doblin (founder and president of the Multidisciplinary Association for Psychedelic Studies, and one of the most influential figures in psychedelic science) returns to Mayim Bialik's Breakdown for one of the most controversial and eye-opening conversations on psychedelics we've had yet.From the shocking experiment where scientists gave MDMA to an octopus, to why ibogaine may be the most powerful AND dangerous psychedelic ever studied, this episode explores the future of psychedelic therapy, trauma healing, addiction recovery, policy reform, and human consciousness itself.We break down Trump’s new executive order accelerating psychedelic research and what it could mean for the future legalization of psychedelic-assisted therapy in America. Dr. Doblin explains why veterans suffering from PTSD and disabilities have become central to bipartisan support for psychedelics, and why this issue is now reshaping politics on both sides of the aisle.We also dive deep into ibogaine: its mysterious origins, its ability to help reset opioid addiction, its connection to ancestral memory and intergenerational trauma, why it carries serious risks, and why Dr. Doblin still believes its benefits may outweigh the dangers. He also shares his own profound ibogaine experience that helped him confront perfectionism and his fear of death.Dr. Doblin discusses:- How psychedelics help people integrate trauma- Why psychedelics are generally considered non-addictive- Difference between recreational vs therapeutic psychedelic use- Why psychedelic treatment should be customized to each patient- Importance of integration, peer support, and paying attention to dreams after treatment- Measures of success in MDMA-assisted couples therapy- Origins of the opioid epidemic- "Psychedelic churches": How organizations are openly operating under the umbrella of religion- Capitalism vs democratizing the benefits of psychedelic medicine- How a better psychedelic therapy model could be built- Why transparency is critical for science-backed drug policy reform- When psychedelics may realistically enter the open market- Dr. Doblin’s long-term vision for a psychedelic-informed publicAs psychedelic research rapidly expands worldwide, this conversation explores the science, politics, risks, ethics, and revolutionary potential behind one of the fastest-growing movements in mental health and medicine!DISCLAIMER: MBB is not providing medical or legal advice. Listeners should speak to their doctor before engaging in any course of psychedelic protocols. Psychedelics are still illegal in many places - MBB is not encouraging engaging in illegal substance use, but simply sharing the latest scientific insights from our guests.Learn more about MAPS & their research: https://maps.org/To learn more about the world’s largest psychedelic conference, Psychedelic Science, taking place in Denver, CO next year, visit: https://virtualtrip.maps.org/Rula patients typically pay $15 per session when using insurance. Connect with quality therapists and mental health experts who specialize in you at https://www.rula.com/break/ #rulapodText BREAKDOWN to 64000 to get 20% off all IQBAR products, plus FREE shipping. Message and data rates may apply.Head to https://www.Superpower.com and use code BREAK at checkout for $20 off your membership. Unlock your new health intelligence. 100+ biomarkers. Every year. Detect early signs of 1,000+ conditions. #superpowerpodFollow us on Substack for Exclusive Bonus Content: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bialikbreakdown.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BialikBreakdown.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube.com/mayimbialik⁠⁠⁠See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We're at a moment that has been building for well over half a century. Psychedelics were blossoming in the 60s, and then we have the Nixon crackdown. What's just happened for the first time is that the Republicans have become champions of psychedelics. We're not talking about tripping balls. We have the power to change your brain. There will be $50 million coming out of the federal government for psychedelic research. My prediction would be five to 10 years. There'll be 10,000 psychedelic clinics all over America.

Dr. Rick Doblin is the founder and president of MAPS, the Multidisciplinary Association for Psychedelic Studies. His goal is to harness psychedelics to change the way we think, feel, and live. One in six Americans is on an SSRI. New drugs for mental illnesses are about controlling symptoms and not getting to the root cause. The goal is for therapists to be cross-trained in LSD, MDMA, psilocybin, and then they customize treatments. The big worry about the for-profit psychedelic companies is they want to run away from therapy. When you don't do therapy, you don't take advantage of the neuroplasticity. People need to buy more of the drug. That's this capitalism versus altruism.

We want a psychedelically literate population that has learned about psychedelics for prevention, spirituality, connection. You don't change an old model by criticizing it. You change it by creating a better new model. Mine Be Alex breakdown is supported by Helix Sleep. Summer's in the air, and so are all of the allergens that come with it. Summer allergens means you need more sleep, but there are a ton of factors that can prevent us

from getting a good night's rest. Night sweats, back pain, feeling the person next to you when they roll over. We are so excited that Helix wants to partner with us. I've had my Helix for, I think, over five years now, and I sleep so great. Jonathan and my kids also love their Helix mattresses and all of those issues. Night sweats, back pain, motion transfer, significantly better, or gone. Helix delivers your mattress right to your door

with free shipping in the U.S. They have a 120-night sleep trial and limited lifetime warranty, plus they're happy with Helix Guarantee. Rest easy with seamless returns and exchanges. The Happy with Helix Guarantee offers a risk-free, customer-first experience

designed to ensure you're completely satisfied with your new mattress. Go to helixleep.com slash breakdown for 20% off sitewide. That's helixleep.com slash breakdown for 20% off sitewide, Helixleep.com slash breakdown. Hi, I'm I'm Bi Alec.

And I'm Jonathan. And welcome to our breakdown. There's a huge set of changes occurring in the government and in our lives regarding the use of psychedelic therapy. Recently, there was an executive order that fast-tracked the FDA to research these medicines, increasing the timeline that they could be available. Are we on the cusp of possibly tens of thousands of psychedelic clinics across the United States, or are the pharmaceutical companies setting us up for their profit over our healing? Our guest today is Dr. Rick Doblin. We've spoken to him before.

He's the founder and president of MAPS, the Multidisciplinary Association for Psychedelic Studies. His professional goal is to help develop legal context for the beneficial uses of psychedelics, primarily as prescription medicines, and for a very, very specific. and fascinating set of cases. Dr. Doblin's going to explain how MAPS just celebrated its 40th anniversary. So much has changed even in the last five years in terms of how we understand trauma, treatment-resistant depression, and how these medications are actually tapping into the neuroplasticity that the human brain is utilizing to change the way we think, the way we feel, the way we live. And in particular, for veterans and for underserved populations where rates of addiction, rates of abuse, rates of trauma are higher, how can we get more people the help they need

without falling into a pharmaceutical mess? There is so much potential on the horizon, but Rick highlights the one major mistake people are making with psychedelics. You do not want to miss that. We're also going to talk about Ibogaine and the recent conversation about can this medicine actually change the way we see the opioid crisis, the way we view addictive. in general, or is it another way that we're opening ourselves up into a world that we don't yet fully understand? We're so excited to welcome back to the breakdown, Dr. Rick Doblin. Break it down. It's fantastic to be here. I'm really delighted. Always excited to talk to you, but we're especially excited to talk to you in this moment. Can you start us off by sort of giving us a lay

of the land of where psychedelic research is, and in particular, what moment we are in at this time in history? Well, we're at a moment that has been building, I would say, for well over half a century. So 1970, we have the Controlled Substances Act and criminalizes psychedelics, and then Nixon decides to really launch a global international war on drugs, and that wipes. out psychedelic research. So for decades, there was no psychedelic research anywhere in the entire world. That was sort of the peak of American power. And one of our worst exports was the drug war. So beginning in 1992, a new group of people took a hold at the FDA that were reviewing psychedelics. And actually, it shows how different social justice movements sort of intersect with each other

because it was the AIDS movement, the act up, that felt that the FDA in the 80s, when people were dying right and left from AIDS, that they felt that the FDA was overly focused on risk and not enough on potential benefits, particularly for life-threatening diseases. And so they had a protest act up around the FDA building, which they'd never, ever seen before. And then in response to that, the FDA created this group called the pilot drug evaluation. staff that was to pilot new ways to evaluate drugs more quickly. In a way, kind of like the national priority vouchers that Trump has just awarded, you know, in this executive order. But anyway,

that group decided to open up the door to psychedelic research for beneficial uses. That happened in 92. So then we were really, Maps at least, was doing safety studies with MDMA. Then research started in the end of the 90s with psilocybin. And then we basically had about 25, years of enormous investments. Right now, the nonprofits, which began this research, have raised somewhere in the neighborhood of $300 million in donations to bring us to this point. But the pharma industry has now put in investors close to $6 billion. So we are at this stage where there's just an enormous amount of psychedelic research taking place not just in the U.S., but in many, many places of the world.

Not in certain places like Russia, China, North Korea, places tragically like Ukraine, which we've gotten a $240,000 donation from the Open Society Foundation, from George Sorosius Foundation, to train Ukrainian therapists. But Ukrainian laws are left over from Russia, and they create. criminalized research with Schedule 1 drugs. So until MDMA is made a medicine somewhere else or psilocybin or until they change the law, nothing can be done in Ukraine. But we've got an enormous amount of research.

And I'd like to refer people to psychedelic alpha if they're interested in. It's a newsletter for investors in this area, but it does the best to track what's going on. And they have what's called the bullseye chart, which I'd never seen before until they did it, which was great, which is at the center of the bullsize. is FDA approval. And the only thing that's in the center of the bull's eye is spravato, an isomer of ketamine by Johnson & Johnson, which was approved without therapy and I think is a real bad model for what's best for patients. But it's a great model for what's best for shareholders because when you provide ketamine without therapy, the results not very durable and then

you just keep needing to buy more and more ketamine. You pride it with therapy, the results are more durable, but the pharmacominy doesn't make any money on the therapy. Okay, so we've got the bullseye is only spravado. But in the inner ring of phase three studies that are either been completed or national priority vouchers, we have quite a few entries in there. Usona, which is a nonprofit that's working out of Madison, Wisconsin, on psilocybin for major depressant, depressive disorder, compass pathways, which is psilocybin for treatment, resistant disorder, they're probably going to be the first one through right now. Then there's

LSD for generalized anxiety disorder, 5MEO DMT for depression. There's a series of these that are either close to completed or completed with phase three or in the review process. And then in phase two, there's a lot more, phase one, preclinical. So there's just an enormous. And I think what's just happened for the first time, which I think would, you know, you know, shock many people if they haven't heard about it, is that President Trump, the Republicans, have become champions of psychedelics. And I think that's because of the strategy that we embarked on a long time ago to try to get bipartisan support, in part through working with veterans and others. Why has psychedelic research become a political tool? What is actually happening?

Well, I would say the opposite in a sense is that our strategy was to take. take psychedelics out of the culture war so that they would not be, you could say, coated red or coated blue or that they would. So psychedelics were definitely counterculture, anti-Vietnam war, pro-environmental rights, pro-civil rights, pro-women's rights. And also the reason being, expanded consciousness allows for a lot of opening. And if you were to, if you had to decide which kind of politics would more align with opening, consciousness, more love, more sex, more beautiful in touch with your body, you would say, okay, that feels like a, like a democratic or a liberal or a progressive kind of thing.

So that sort of pitted, right, that movement against people like Nixon, who were known for wanting to keep things the way they were, keep the sort of conservative order, whatever that means, American values, whatever that means, the patriarchy, right? All that stuff. So then you have this alignment of people associating. this kind of movement and consciousness opening with, let's say, the Democratic Party. So explain now what's flipping. Okay.

So one of my favorite moments of the White House hour-long signing ceremony with Trump signing this executive order was this other podcaster, Joe Rogan, standing behind Trump and over his shoulder explaining to him why Nick. and criminalized psychedelics. And what Joe Rogan was explaining to Trump was that, and this comes from a quote from John Erlichman at the end of the 70s in an interview with a journalist Dan Baum, where what Erickman said is that the two main enemies of the Nixon White House

were the hippies and the civil rights movement. And he couldn't stop them from protesting, but if they could criminalize the drugs that they were using, and use the drug war to bust up their meetings, arrest their leaders, stick them in jail, that they would do that. And then Erlichmann said, did we know that we were exaggerating the risks of drugs? Of course we did. So the psychedelics have been underground for thousands of years.

And let's just go back a very beginning, which was from 1600 BC to 396 AD was the Ellicinian Mysteries. And this is the foundation of Western culture, the Greek. Brian Merarescu wrote an entire book about this mysterious kind of, yeah, a cadre of humans who opened their consciousness in a variety of ways to understand the mysteries of our existence and the universe. Well, a variety of ways, yes, but they all drank a potion called Kikion. Yes. And then they marched a couple hours to Elusis where they had the ceremony. It was under pain of death. You couldn't say what was in it.

And to show what they really thought about it, this is kind of amazing. speaking of the patriarchy, but they said that women and slaves could participate in the Ellicinian mysteries, but it involved the psychedelics. And it's not exactly clear what was in the Kikian, but Albert Hoffman, Gordon Wasson, who helped bring us LSD and mushrooms, they speculated that it was an air got, a fungus on the weed and rye, and that it had LSD like components and that they were all tripping, and everybody that we think of from the history of the Greeks, Pythagoras, Aristotle, Plato, Socrates, all these people, Archimedes,

they all had these experiences. And it was wiped out by the Catholic Church because the power structures, in many cases, don't want you to have a direct connection to spirituality. Of course. And, right, and also, you know, drinking the blood of Christ, what Brian Morescu talks about

is that is one of these remnants, right? Yeah, yes. Of a time when ingesting something meant you became, one with it. And I remember as a kid, I was like, how could they think that Christ is in the liquid? And then when I read Brian Murrescu, it made sense because the only other time that happens is when you break through the realm of consciousness and you become one with the universe and then you are drinking the blood of God. And it all makes sense. And you have a revelation.

So yes. It all makes sense. Yeah. So then we have the conquistadors and all that. We have the middle ages, the burning of the witches. We have the conquistadors who see peyote and mushrooms as sign of the devil, but also those were often the center of the community. So those would be the first people that would be killed, would be the shamans and the people that worked with a non-ordinary story. Mymbialx breakdown is supported by bioptimizers. We're very excited to share with you our new nighttime ritual. We tried magnesium breakthrough by bioptimizers. And we can say that this is definitely different. Most magnesium supplements have only only one or two forms. This one combines seven different forms of magnesium plus co-factors

to help your body better absorb and use it. What are the benefits? Oh, you know, better sleep, feeling calmer, better recovery from workouts, even better digestion. We've definitely noticed improvements in our sleep and digestion since trying it. We recommend that you try it, track your sleep. Notice how you feel, see if you wake up more refreshed. You've got nothing to lose and everything to gain. And here's the thing, bioptimizers is so confident in their product that they offer a 365-day, no questions-asked, money-back guarantee, zero risk. Here's what you get when you go to buy optimizers.com slash breaker

and use the code breaker. You get 15% off your entire order and a free bottle of mass zimes added to your order automatically when you use our exclusive code. That's a $20 product free on top of your discount. This is a limited time offer and only while supplies last. You cannot get this on Amazon. You can't get it in stores.

The offer exists in only one place. our link, our code. That's it. So if you were already thinking about trying it, this is the sign. Go to buy optimizers.com slash breaker and use codebreaker and get it before it's gone. Mine be Alex breakdown is supported by OneSkin. Whether you try every new skincare product or you've been using the same things for years, at some point your skin is just not going to keep up the way it used to. That's what One Skin changed for me.

It didn't just make my existing routine better. it actually works differently than anything else that I've tried. As we age, some skin cells stop functioning the way that they should, and they cause fine lines, loss of firmness and dullness that creeps in over time. One Skin's OS1 peptide was specifically engineered to address those visible signs of aging. So you get everything you expect from great skin care and OS1 doing something most skincare was never built to do. One Skin's results are backed by four peer-reviewed clinical studies, over 10,000 5-star reviews, and they've been recognized by Bloomberg as a leader in skin longevity.

You really don't need a complicated routine to get healthier, younger-looking skin. One of our favorite things is that they are rooted in rigorous scientific research. With One Skin's face SPF, it's got the same science-backed skin care benefits from the OS1 peptide, while also giving you mineral SPF protection from UV exposure. Reverse aging while having lots of summer fun. Born from over a decade of longevity research, One Skin's OS1 peptide is proven to target the visible signs of aging, helping you unlock your healthiest skin now and as you age, For a limited time, try OneSkin with 15% off using code break at OnSkin.co slash break.

That's 15% off, Onskin.com with code break. After you purchase, they'll ask you how you heard about them. Please support our show and let them know we sent you. My M.Bi Alex breakdown is supported by Mudwater. Jonathan and I have taken the plunge. We are into mudwater and we love it. I especially love their turmeric latte. Makes us feel energized without the jitters.

That's why we want to tell you. about the starter kit because it's genuinely the best way to get into mudwater. If you're one of those people who loves the morning routine of coffee, but the caffeine sends you straight into an anxiety spiral, mudwater provides the same morning ritual, but with functional mushrooms and adaptogens instead of a full caffeine hit. Steady energy, no spiral. The best way to start is the starter kit.

It's designed to set you up with everything you need to build that habit. When you order, you get the full-size tin of your chosen blend, plus a free rechargeable frother, free gifts, free shipping. There are four flavors. OG, that's the original chai chocolate blend, coffee, matcha, and turmeric. So if you're a coffee person, a matcha person, a chai person, or something in between, there is something for you.

Ready to make the switch to cleaner energy, go to mudwater.com slash break. Grab the starter kit, use code break. You'll get 43% off. The frother alone is worth it. That's right, up to 43% off with code break at M-D-W-T-R.com. It's a fantastic frother. After you purchase, they'll ask you how you found them. please show your support and let them know we sent you.

Straits of consciousness. Then we have this blossoming in the 60s, and then we have the Nixon crackdown. And so I think what's happened since then has been two major things. One has been, in some ways, the tremendous success of the pharma industry in coming up with new drugs for mental illnesses.

But then the recognition that these drugs almost always are about controlling symptoms, and not getting to the root cause. And conveniently for the farm industry, there's stuff you've got to take every day, often for the rest forever. Yeah, there was a great article actually today in the New York Times about psychiatry starting to talk about how to teach people

about tapering off of their psychiatric medicines. One in six Americans is on an SSRI of some kind. It's just enormous. But there was this growing recognition of the limitations of that approach. and also this sense that there was a lot of people that didn't even get symptom control, that were treatment resistant, that didn't get help, were more prone to suicide. And then we have the rise of what actually, when I started MAPS in 86, the big focus for me for this bipartisan support was Vietnam War veterans. At the time, there was several hundred thousand of them who had PTSD.

and it was costing the VA, you know, in the neighborhood of $4 billion. Now because of Iraq and Afghanistan wars, and who knows what's going to happen because of this Iran war. In other words, there's over a million veterans on disability for PTSD. It costs the VA somewhere in the neighborhood of $17 billion a year just on disability payments. So what I like to say is that MAPS, the nonprofit that I started in 86, we just had our 40th anniversary, on April 8th. Well, conveniently, we had our 40th anniversary party in San Francisco on April 18th, which was the exact same day, the executive order came out.

And just this, it really added a lot of... Almost 420. Almost 420. But it really, well, and 420 is more about marijuana. 419 is Bicycle Day, which is more about psychedelics. And so this was 418. And that's when our party. And so what we've had is this growing use of psychedelics by veterans.

And I think one of the more notable ones that led to this White House meeting was the drug Ibigain, which I was about to say I had the pleasure, but I wouldn't say it was a pleasure. I had the grueling experience of having a highly beneficial experience, which is one of the most important experiences of my ever life, of my whole life with psychedelics, which was a mixture of LSD and Ibegain, which I did in 1985, given to me by this fellow Leo Zeff, who he called the Secret Chief. So he was the leader of the underground psychedelic therapy movement.

And actually, Ibegain had been introduced in the US in the 60s by Claudio Naranjo, who was also a Jewish psychiatrist from Chile. And so it was then in the 60s that Howard Lotzoff, who was addicted to heroin, but also interested in psychedelics, tried Ibegain and woke up without any way. withdrawal symptoms after he did the ibigate. So we've had a lot of Navy SEALs go down to Mexico and other special operators receive Ibigate. And then often some of these clinics would give 5MEODMT, which is the toad, which is very short acting, you know, days after the Ivocaine.

So that really developed this incredible constituency, including Marcus and Morgan LaTrell, brothers who were both Navy SEALs, one of which is in Congress, and they've had their own experiences with Ibegain. And I think the big transformation has been Rick Perry, who was the former governor of Texas in Trump's first cabinet, and he and I have become allies. And he's become really allies of this entire movement to the point where he himself has gone down to take Ibegain. And so they were able to get $50 million from Texas for Ibegain research. Obviously, you know, consistent with disclaimer, this is a very, it's a very, you know, it's a, I want to say that it's a complicated medicine in that, you know, we're still sort of learning what and how the sort of mechanisms

are. And also there's tremendous variability, you know, and this is one of the things about the kind of research that you do and support is that we're taking medicines, right, that are tapping into, in many cases, your deepest kind of wounds, your deepest loves, you know, your formative memories. You know, some might even say ancestral memories. And those things don't follow a predictable course, which makes them so special and interesting to study. And that's why integration and therapy is so important because it's not like taking ibuprofen, right?

It's not like taking a medication where, okay, this is generally speaking what's going to happen. Many things get opened up, right? So when we talk about ibogaine, maybe you can tell us a little bit about its history. What was unique about your kind of therapeutic experience you had with it? Also, maybe you can explain a little bit what it means to have ibogane and LSD and sort of what that chemical compound opened up. Yeah, although just to clarify, so I had iboga the root, not ibogaine the extract. And the clinics now are using ibogaine the extract.

and it has really unusual properties. I mean, the thing that Ibegain does or Iboga does that no other psychedelic does that we know of helps people go through the withdrawal from opiates and resets your brain so that even in a couple days you are no longer addicted. That's actually a danger in some ways because of people then relapse

and they use the same dose they'd used before. Now their brain is reset and they can over. overdose and die, and that has happened sometimes. So Ibigen has that unique property. In other aspects, it's like other psychedelics in the sense that it opens the, you could say that there's a membrane in a way between conscious and unconscious mind that we all experience during our dreams at night. But through meditation, through fasting, through all different mechanisms, people have found

that there are ways to sort of open up this. permeable membrane and have things emerged, you know, artists talk about it or being in flow. People talk about being in flow. So that when things emerge with psychedelics in general, people talk about Ibegain as more about connection to ancestral, ancestral memories. I didn't actually have that experience. But I do want to just briefly speak about Rachel Yehuda. And she's done work with Holocaust survivors and their children.

children and identified epigenetic mechanisms by which stress levels, anxiety levels, are passed on from parents to child. Yeah, we've talked about this intergenerational trauma and how there actually is a science to it. It's not just anecdotal. And she obviously is, you know, someone we've spoken about a lot in terms of this research. So, yeah. Yeah.

And then she's also been doing some studies recently to show, does successful therapy change these epigenetic markers? and there's preliminary evidence that it does so that it doesn't mean MDMA therapy, which is what she's looked at, but just successful therapy of any kind. Just to say we're also getting ready, this is a slight tangent, but we're getting ready to work with MDMA with couples therapy where nobody has a diagnosis. So we've got a project at Columbia University, which is to interview underground MDMA therapists all over the world to see how they work with couples with MDMA.

And the most unusual one is a husband-wife team outside of Mexico City. And they specialize in working with couples before they conceive a child. Oh, my goodness. In order to work through the traumas that produce these epigenetic mechanisms so that they don't pass on multi-generational trauma to their kids. I mean, talk about a longitudinal study. Like when my kid is 60, do I have a right to say? It didn't work.

It didn't work. perhaps yeah and you know again probably they need their own therapy as well but so with ibegain so to zero to zero in on ibegain um ibegene is also the most dangerous of all the psychedelics in that it has an impact on the heart on qt prolongation and one of the challenges and one of the things that we're going to see um about this executive order white house what it really means is that the FDA has a cutoff for QT prolongation. And I think it's 500 milliseconds or something. And if anything is over that amount,

then they'll say it's too dangerous to use. However, IBA almost always produces something that's, you know, over that amount. And so currently the FDA has put an IBEA project on clinical hold. Wait, and you're talking about QTTT prolongation, in terms of heart, correct? Yes, in terms of heart, yeah. Yeah, so one of the things that happens with a lot of these medications

that people may not realize until they're kind of in it and think they're dying, a lot of these medicines do have physiological effects, which in some people can be dangerous. Yeah, I think so. I think that in the Buiti, so Ibegain was really,

it's from Gabon, Western Africa. It's used in this Buiti religion. It goes back hundreds, if not. thousands of years. And they have various techniques to try to keep people safe. You know, they make people stand up and walk around and do various things instead of just lie down the whole time. To regulate some of these interesting ventricle and heart things that can happen. Yeah. Yeah. Yeah. So I began in the clinics that are responsible is administered under medical supervision, often with an IV and often magnesium or things are given in order to try to help

with this QT prolongation issue. So I believe that IBM can be administered safely under medical supervision. There's clinics that have had thousands of people without anybody dying, but occasionally somebody will die. So it's not 100 percent you can eliminate this. It's a little bit of an unknown. However, many, many medical procedures have a risk of fatality. Knee operations are not so great for, you know, sometimes people die under knee operation, knee replacement operations. So what you need to do is what the FDA always is supposed to do, is balancing risks and benefits.

So what is the risk of untreated opiate dependence? It's often fatal. So in any case, I believe that a rational risk benefit analysis with Ibegain under medical supervision can pass the risk-benefit test. I think there's going to need to be a challenge to the FDA about what they have is an unreasonably low cutoff point, and they're ignoring evidence that unfortunately was not gathered under FDA clinical studies, but gathered in these clinics in Mexico, New Zealand. So around 12 to 15 years ago, maps. did two studies with Ibegin.

It had never really been studied because it was always being used outside of the United States. Ibegain is criminalized in the United States, but it's legal in most of the world. So in our zeal to criminalize things in the U.S., we criminalized Ibegain, which does not have an abuse liability. People, you know, Brian Hubbard said something really funny, which was, you know, if your idea of lying down for 12 hours vomiting and not being able to walk for another 24 hours, the idea of fun, yeah, then Ibegaine has abuse potential. But, you know, people don't abuse it. In any case, it's schedule on the U.S., but it's legal or not illegal in most of the world. So it's not illegal in Mexico. So we did the first study ever at these clinics, one in Mexico,

one in New Zealand, and we used the addiction severity index, which is the standard measure for addiction. And we would test people at baseline in these clinics, and then one month, every month for a year to see the long-term follow-up. So this was called an observational study. We were not administering the Ibigain so we could do this with IRB approval, and we showed that it was pretty promising. I think the idea of one-dose miracle cure and people are done forever is not true. Occasionally that works, but often people talk about wanting to get another treatment,

a year later, six months later, or treatment of other kinds. but it really does reset people from the dependence and gives them the psychological experience of getting to the root causes. So I think one of the things that comes up, and this is absolutely not my perspective, but I think one of the things that we're up against with a lot of psychedelic research, at least, you know, from a layperson's perspective, is there are certain kinds of people that many individuals are comfortable helping. and there are certain kinds of people that the powers that be kind of want to push off to the side. And, you know, I was born in 1975, right? So kind of after the Vietnam War and, you know, you would meet people and my parents would

very lovingly say, like, that's called shell shock, right? Or we would meet someone and they would say, like, you know, he went to Vietnam and, you know, he didn't come back the same, right? And I think there's sort of this notion and I think veterans is one kind of. category, right, where people kind of just think like, oh, you went to war and now you're old and crazy and like, sorry. And then when we talk about, you know, addiction, I think that a lot of people still view this kind of addiction, opioid addiction in particular, as a moral failing. Like, these are people that made a lot of bad decisions and they're poor. And this is also where we do get a

partisan conversation, which I think is kind of ironic, right? Whereas, you know, the Democratic party or that kind of progressive liberalism says the system has wronged you and it is our party's responsibility to help make that right with a variety of programs and support. And the sort of Republican or more conservative perspective is pull yourself up by your bootstraps and like trickle down economy and all these things. And if you can't cut it, that means you're not supposed to be a CEO, right? So I wonder if you can speak a little bit about some of the kind of heart opening that this kind of research allows for us to be able to say there's a much more complicated story as to how we got here.

And in many cases, it was the government's support of opioid drugs and distribution that got us into the situation. And I don't mean to be that hippie, but like a little bit, I'm that hippie. So, yeah. My Ambialx Breakdown is supported by no CD. Have you ever found yourself replaying conversations over and over, worried that a friend secretly hates you, or maybe you've spent hours researching some minor ache, even after a doctor said you're fine, but your doubts and fears just won't go away.

Distressing unwanted thoughts that get stuck in your mind and make you feel you have to try to solve a problem can actually be a sign of obsessive-compulsive disorder. OCD is nothing like the stereotypes about liking things organized. It's a serious condition that can focus on anything. Your identity, your morals, your relationships, your sense of reality, and what makes it so debilitating is that it often fixates on exactly the things that you care about most. I've actually struggled with OCD myself. I know how misunderstood it is and how hard it can be to get the right kind of help. And that's why we're here to tell you about NoCD. NoCD is the world's leading provider of specialized OCD treatment. Their licensed therapists go

through extensive specialty training to identify and effectively treat OCD. In live, face-to-face virtual sessions, they'll help you reclaim your time, your confidence, your freedom. NoCD is covered by insurance, which is amazing. for over 138 million Americans and includes support between sessions so you never have to face OCD alone. If any of this sounds like you or someone you love, head over to nocd.com and book a free 15-minute call with their team. That's N-O-CD.com to learn more and get matched with a therapist who can help. Well, let's go back a little bit to the pilot drug evaluation staff, which I mentioned was formed after ACT UP. That was the group that formed around.

1990, and I think around 1996, it was eliminated at the FDA. But during its short history in 1992, as I said, it opened the door to psychedelics, but it also opened the door to OxyContin. And so it's the same sense of sort of reducing layers of review. And then this scandal sort of is that the fella from the FDA then went to work for Purdue Pharma after he left the FDA. So the idea that these opiates have addictive potential, you know, it's really an enormous scandal about this sort of collusion in a way between the pharma industry, the FDA, and all about what's best for shareholders, which is just sell more stuff. I mean, it makes me want to burn it all down, like literally. Like, I mean, I've watched every single documentary and every single non-documentary, you know, about this. Like, this is one of those things, like we should be rioting in the streets.

And also, when you mentioned Act Up, you know, let's include in that category of people that at that time in particular no one cared about. There was a crisis that was striking deep into the homosexual community, the LGBT, you know, what we now see is the LGBTQ kind of larger community. And no one cared. Like, I mean, some people cared, but no one that could actually have done anything cared and we're kind of seeing that play out. So it's interesting, you mention that. Like, there are these populations that people are happy to dismiss. And I think now we're having this

reckoning of what does it actually mean to have these crises? Yeah, I think so. I mean, I think that was this idea that AIDS is a plague from God for being non-ordinary, you know, in your sexuality. So I think that this raises really an important issue about what I like to say about maps is that we don't just do science, we do political science. So most of the people that have addiction, you know, we think of them as the other. So psychedelics can be great for addiction. So the fact that now we're talking about, Ibegain, although it's mostly in the form of PTSD and traumatic brain injury, not so much in the form of opiate addiction. So because many of the veterans have traumatic brain

injury from all these explosions and they, you know, have PTSD from what they've been through. And many of them are also addicted to the pain meds and stuff. But the focus has been. So addicts are generally the other. Most that's why MAPS chose MDMA of being the most gentle of all the psychedelics, but deeply profound and the most ideal, I think, for PTSD. And veterans as being a sympathetic patient population. However, most of the people in America that have, PTSD are women, survivors of sexual abuse or domestic violence. But there's not one single woman's group that I'm aware of that supports research into the treatment of PTSD, not one. And there are loads that support research for veterans. So veterans were the way in which we really

began to get bipartisan support. And I think that that was, again, both a political decision, but also a compassionate decision. But when you have a culture that has demonized psychedelics has spread enormous misinformation, you need to go to where the suffering is and where people care about that suffering. And so that became MDMA for PTSD. We began, our first study was women survivors of sexual assault. And near the end of that study started to be the Afghanistan wars and then Iraq. And so then we started adding veterans into our studies. And then for political reasons, but also, again, this idea of working on all sides of the conflict, we did veterans, firefighters, and police officers. And we didn't think we would actually get any police officers in the study, but we just wanted to say, hey, it's open to police officers because they have terribly traumatic jobs.

And they're told to just go back to work to not think about it. they see the worst of humanity and they're given no support. So many of them are alcoholics. They commit lots, commit suicide. So in the end, we did get both firefighters and police officers as well as veterans. So that was the way we started building bipartisan support. And I think that the work that was done initially with psilocybin was trying to do this in a similar way, but with people who had cancer or other life-threatening ill. So we're all going to be facing death one day, except for these tech people who think they can live forever, you know, who are utterly disconnected from the reality of human life, you know. But I think, and I think they'll end up dying too. But working with people who are dying is another way to talk about sympathetic patients.

So while MAPS began with MDMA for PTSD, this group Hefter Research, Counsel on Spiritual Practices, working with Johns Hopkins, with Roland Griffiths and others, Tony Boses and others at NYU, they focused on cancer patients and people with other life-threatening illnesses. So there's always been a political element to this, but the Ibegain is the one that also people were going outside of America to get treatment. And they were saying, we're giving our service to America. And now we have to leave the country to get treatment. And nothing you're doing is helping us.

And you're just over-medicating us and giving us all these multiple prescriptions for SSRIs. They interact with each other. They have serious side effects. And so it was really this rise of the Ibegain movement. But I would say what also led to the White House Executive Order was all of these settlements. So this is the upside of tragedy, you could say, is the billions and billions of dollars that the pharma industry had to pay to states to deal with the opiate dilemmas that they caused, the opiate problems. And then we were up to, you know, 100,000 plus a year people dying from fentanyl and opiate overdoses. it's declined a little bit since the last couple years where it was that high.

But that led to all these billions of dollars going to states. And then Brian Hubbard in Kentucky was working with the Attorney General's office, and he decided to try to allocate some of the money that was going for treatment of symptoms of people to turn it into research with Ibegade. I think a lot of people don't want to think about this, which I completely understand. But can you sort of explain, you know, what was going on that led to the government feeling the pinch of this that made a conversation about actually trying to get to the root cause of some of these problems possible? Well, what was going on in many areas of the country, not just the cities, but often in rural areas where jobs were disappearing. and where people had jobs that they often had to physically do work, and that would, like in mining and stuff,

and they would end up having different kinds of pain. So there was starting to be pain meds in a lot of these places. And then what happened was pill mills. And so it was pretty obvious that the amount of prescriptions that were being filled in certain areas were way more than everybody in the whole county or whole city could reasonably use. Dope Sick shows this very well. And I think this is something, even just to frame what you just said, you know, for people who who have blue collar jobs, right, for people who are doing manual labor and with less jobs being available, people are working extra shifts, people are over, literally over-exerting, which is leading to the kind of things that most people don't want to think about. It's leading to physical pain and injury and a need to get back to work quickly.

quicker, right? We don't have that luxury. If you're in a, you know, a single parent family and you have a blue collar job, you do not have the luxury to recover, right, from an injury. So we need medications that make you able to literally get back to work so that you can try and put food on the table. So you get this sort of like dynamic in these places where blue collar jobs and manual labor is kind of the mainstay and you get these enormous needs, which obviously is very, very addictive and you need higher and higher doses. Yeah, and then the pharma companies are more than happy to provide higher and higher doses escalating every way without any kind of real thought about the addictive potential of it.

This created the epidemic. Yeah, yeah, it was very much a pharmaceutical company empowered by FDA with very limited oversight, but what was happening was the shareholders were happy. And so one of potential donors spoke to us about how he said MAPS was walking the tightrope between capitalism and altruism. And so I would say in general, the pharmaceutical industry is not about altruism. It's not about what's best for patients. It's about capitalism. It's about what's best for shareholders.

When MAPS created the MAPS Public Benefit Corp, the for-profit company that we thought would move MDMA through the system and then be able to market it, we created it as a public benefit corporation. So just as a brief sideline here, the public benefit corporation is a modification of capitalism where with a traditional company, you have to maximize profits. And minority shareholders can sue the management if they don't think they're maximizing profits because that's their mission. So it's like cancer, this growth without any kind of concern about externalities, the growth that eventually kills the host. But with this public benefit corporations, you put whatever you define as public benefit over making profits so that you can maximize public benefit. And the way I interpret that is public benefit is what's best for patient, not what's best

for the shareholders. It's what's best for patients. And it can still be good for shareholders. But we had capitalism run amok, and then we had Purdue Pharma and other companies along the distribution chain, just pumping out enormous amounts of these pills that any person looking at it would say these are not going to the people that are getting the prescriptions. They can't use that much. This little town can't have that many people that need it. So the recognition then started showing up in deaths and what's been called deaths of despair.

Now, this is often in rural areas, but it's not only. I mean, rich people get addicted and also die, but this was deaths of despair where deaths from alcoholism, suicide, and drug overdoses. And they just kept rising and rising and rising as the shareholders get making more and more money. And finally, it became clear that there was this nexus between the over-prescription of pain meds and the opiate epidemic. And so the Purdue Pharma and other pharma entities

were then sued by various entities, either the government or individuals, and they were forced to disgorge billions and billions and billions of dollars of ill-gotten gains and give them to the states to try to remedy the damage that they had caused. And so this money, Kentucky, actually got $840 million.

one state. And so Brian Hubbard, working in the Attorney General's office, had heard about Iveyane as more of a cure for this opiate dependence, which it is. Whether it's a cure for the underlying issues depends on the integration. It's not just here's the pill and then that part's cured. But Brian tried to get, you know, 42 million, 5% of the money that was going to Ibegain. And he got a long way. He had hearings. He went a long way to do that. And then the Attorney General and other people in the administration who had been involved previously as lawyers for the pharma industry killed it and fired Brian. But fortunately, he kept working in other states. And eventually through these connections with Marcus and Amber Capone from a group called Vets that was sending a lot of veterans down to Mexico. Mexico for Ibegain. You know, Rick Perry heard about it.

Rick Perry heard about our work with MDMA with veterans, with PTSD, and so we started building this support. And then over time, what's culminated now is $50 million from the state of Texas, and it looks like it's going to be matched by $50 million from federal money to develop Ibegain. And then there's other states that are trying to come through. The problem, as I would see here, is what is the entity that? that's going to be the pharma company. And so what we see so many times

is public money is turned into private profit. So what I'm hoping, and I don't know if this is going to happen, is that there be a public benefit pharma company created just for Ibogaine to be the one that collaborates with all the states and the federal money combines the data and then turns Ibigain into a generic drug, meaning that it will be commercial sales at a competitive price based on the manufacturing cost.

Now, I don't, actually I don't think that's likely, but I think that would be the best outcome. And that's what we need to watch out for because it's now $100 million plus other states of public money. And it shouldn't just be enriching some for-profit company. And in fact, earlier on, there is a company called Gilgamesh that has developed an Ibogaine-like molecule. that they claim they've never tested it in humans, but it doesn't have the impact on the heart as much. And so they said, oh, let's forget about ibogaine. Let's use our molecule. And fortunately, Texas decided not to do that, that they're going to focus on ibogaine. Meanwhile, the FDA has put a clinical hold on a study that was for ibogaine because of this QT prolongation limit.

But I think that will be overcome. and I think that there will be research in the U.S. on Ibegain, and I think that it will end up becoming approved. Gilgamesh, you know, is partnering with Abbey and Columbia University and, you know, NIH. Well, let's just say what that means is Gilgamesh sold a short-acting psilocybin molecule to Abbe. Yeah. For $1.2 billion. And that's because in part because it's a patented substance, whereas psilocybin and these others are

in the public domain and even the uses of psilocybin, MDMA, LSD for a lot of different things are in the public domain. But the other part of it is that they're claiming, and this is, I think, the big concern that I have about the whole industry right now is most of these companies are saying you don't need therapy. You don't need therapists. You just need medical monitors, dosing session monitors, or they're trying to dumb down the qualifications of the person that are with you. They're trying to pretend that they don't do

therapy. And they're trying to grab all of the value as much as they can for the drug and not for the context, not for the therapists. We're going to hit pause here on our conversation with Dr. Doblin. There is so much more in part two that we cannot wait for you to hear. We're going to be talking about some of the incredible research using octopuses to help us understand the mechanisms of MDMA as well as the longevity of neuroplasticity. We're going to talk about what it means to integrate a psychedelic experience as opposed to recreational use, and we'll talk more specifically about MDMA assisted couples therapy. We're also going to discuss Trump's new executive order directing federal agencies to expand research and accelerate how quickly these therapies

can be available to us. Also, what does it take to be a member in a psychedelic church? All of that in part two of our conversation with Dr. Doblin. From our breakdown to the one we hope you never have, we'll see you next time. It's Myambialics Breakdown, she's going to break it down for you. She's got a neuroscience PhD or two. One fiction.

And now she's going to break down. It's a breakdown. She's going to break it down. Myan Bialyx breakdown is supported by Elastique, where science meets style in wearable wellness. Elastique athletics is designed for daily life, travel ready, workout optional, and beauty enhancing.

Elastique fits into your routine with zero extra effort. Their chic sculpting designs provide therapeutic compression while still keeping you looking stylish. Elastique athletics creates fashion-forward compression wear engineered to enhance circulation, reduce swelling, and support lymphatic flow effortlessly. Rooted in science and trusted by wellness professionals, their patented micropearl technology, blends proven results with premium design, making Elastique the go-to brand for wellness that works while you wear it. Endorsed by physical therapists, lymphatic specialists, and featured in Vogue, Oprah Daily, in goop. Elastique athletics are perfect for post-workout recovery, post-surgery recovery,

travel, swelling, fatigue, and sluggish circulation. Their microprone technology is clinically tested to support lymphatic flow, reduce inflammation, and visibly improve skin texture. It's fashion forward compression that doesn't look like compression. Feel the difference in circulation, recovery, and skin smoothness in just one where. Go to the link in the show notes and use the code MyM-50 for $50 off your elastic order. That's M-A-Y-I-M-50 for $50 off your elastic. plastic order.